🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals

← All drug comparisons

Aricept vs Razadyne

Donepezil  ·  Galantamine

Both are cholinesterase inhibitors. Here is how Aricept and Razadyne compare on class, mechanism, dosing, approval and supply.

At a glance

AriceptDonepezil
RazadyneGalantamine
Brand names
Aricept
Razadyne / Reminyl
Drug class
Acetylcholinesterase inhibitor
Cholinesterase inhibitor
Route
Oral
Not listed
Marketed by
Eisai
Janssen (Johnson & Johnson)
First FDA approval
25 Nov 1996
28 Feb 2001
US shortage
Not listed
Not listed

Key differences

What each one treats

AriceptDonepezil

ARICEPT is indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s disease. ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease ( 1 )

RazadyneGalantamine

An oral daily medication used to treat mild to moderate dementia in Alzheimer's disease.

How each one works

AriceptAcetylcholinesterase inhibitor

12.1 Mechanism of Action Current theories on the pathogenesis of the cognitive signs and symptoms of Alzheimer’s disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying dementing process.

RazadyneCholinesterase inhibitor

An oral daily medication used to treat mild to moderate dementia in Alzheimer's disease.

Related comparisons

Namenda VS Aricept Leqembi VS Aricept

Read more

Aricept profile Razadyne profile Cholinesterase Inhibitors All comparisons
This is not medical advice, and not a recommendation of one drug over the other.

Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.

Class and summary text is written by the Priya Life Science editorial team. Label, mechanism, route, manufacturer and approval data come from the U.S. FDA via the openFDA API; shortage status from the FDA Drug Shortage Database. Approvals, indications and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions — a drug approved in one may not be approved, or may carry a different name, in another.